02/09/2022 (Agence Europe) – On Thursday 1 September, the European Commission granted conditional marketing authorisation for two SARS-CoV 2 vaccines adapted to the original virus and the BA.1 sub-variant.
These were a vaccine developed by PfizerBioNTech and another one developed by Moderna (see EUROPE 13012/23), both of which had been recommended a few hours earlier by the European Medicines Agency. Commissioner for Health Stella Kyriakides pointed out that the PfizerBioNTech and Moderna advance purchase agreements had been amended to include a clause guaranteeing the provision of suitable vaccines (see EUROPE 12971/23).Ms Kyriakides stressed the need for citizens to get vaccinated and receive booster doses.(Original version in French by Émilie Vanderhulst)